
    
      Study design: an open-label randomized controlled trial Duration of study: 12 months

      Treatment arms:

        1. Denosumab: a total of 2 doses in a period of 12 months

        2. Oral alendronate: weekly dose in a period of 12 months Target sample size: 220 patients
           (110 patients in each arm)
    
  